Using Brain Scans to Predict Cognitive Decline in Alzheimer's

What was the main objective of this study regarding Alzheimer's disease pathology?

The study investigated the independent and combined ability of baseline in vivo measures of tau pathology, microglial activation, and brain atrophy to predict the rate of longitudinal cognitive decline.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What was the primary hypothesis regarding the relative prognostic value of PET vs. MRI measures in predicting cognitive decline?

The authors hypothesized that while structural MRI might predict decline in isolation, direct PET measures of molecular pathology (tau and neuroinflammation) would better capture this prognostic information.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Why did the researchers focus their analyses a priori on temporo-parietal regions?

These regions show dominant involvement in early neurodegeneration, tau pathology, and neuroinflammation in typical amnestic phenotypes of Alzheimer's disease.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

How was positive amyloid-beta status biochemically determined for patients with mild cognitive impairment (MCI)?

MCI patients underwent 11C-PiB PET, and scans were classified as positive if the average standardized uptake value ratio (SUVR) across the cortex was greater than 1.5 using a cerebellar grey matter reference.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What clinical cohorts made up the 26 patients recruited for the study?

The cohort consisted of 12 patients with clinically probable Alzheimer's dementia and 14 patients with amnestic mild cognitive impairment (MCI) and a positive amyloid PET scan.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Which specific cognitive test was used to evaluate cognitive performance annually over the 3-year follow-up period?

The revised Addenbrooke's Cognitive Examination (ACE-R) was used.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Which PET ligand was used to measure cortical tau accumulation, and what pathological structures does it target?

The PET ligand 18F-AV-1451 was used, which has high affinity for paired helical tau filaments.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Which PET ligand was used to measure microglial activation, and what specific molecular target does it bind?

11C-PK11195 was used, which binds to the 18-kDa translocator protein (TSPO) overexpressed on the mitochondrial membrane of activated microglia.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What anatomical region served as the reference region to calculate the binding potential (BP_ND) of 18F-AV-1451?

The superior cerebellar cortex grey matter was used as the reference region.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Why did the researchers perform separate Principal Component Analyses (PCAs) on the regional neuroimaging datasets?

To reduce the dimensionality of the 15 regions of interest and avoid the statistical problem of multiple comparisons.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What was the result of the Principal Component Analysis (PCA) on baseline grey matter volumes in the 15 temporo-parietal regions?

The PCA identified only a single component encompassing all 15 temporo-parietal regions, which explained 74% of the total variance.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Describe the two principal components identified for 18F-AV-1451 (tau) PET imaging data.

The first component loaded onto posterior temporal and parietal regions, while the second component loaded onto the anterior temporal lobe, amygdala, insula, and hippocampus.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Describe the two principal components identified for 11C-PK11195 (neuroinflammation) PET imaging data.

The first component involved the anterior and medial temporal lobe, while the second component loaded onto posterior temporo-parietal regions and the insula.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

In patient subjects, did the regional levels of neuroinflammation and tau pathology correlate significantly with one another?

No, the correlations between the 18F-AV-1451 and 11C-PK11195 components were not statistically significant, even uncorrected.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

In the Latent Growth Curve Model (LGCM) of longitudinal cognitive scores, how did baseline cognitive performance relate to the rate of decline?

The cognitive intercept and slope covaried significantly, meaning that patients with higher (better) baseline cognitive performance showed a less steep rate of decline.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Which baseline imaging markers were significantly associated with cognitive decline when assessed in separate univariable models across all subjects?

Brain atrophy (MRI), posterior tau (18F-AV-1451), and anterior neuroinflammation (11C-PK11195) were each significantly associated with the rate of cognitive decline.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

In the final stepwise multivariable regression model for patients, which imaging components remained significant predictors of cognitive decline?

Both 18F-AV-1451 components (posterior and anterior) and the anterior 11C-PK11195 component remained significant predictors of cognitive decline.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What happened to structural MRI (atrophy) when included in multivariable prediction models alongside PET biomarkers?

Atrophy was excluded from the final multivariable models, indicating it did not predict cognitive decline over and above the direct molecular PET measures of tau and neuroinflammation.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

How did the Bayesian multiple regression analyses support the findings regarding the prognostic value of structural MRI?

The best-fitting Bayesian model excluded structural MRI, confirming evidence against its predictive value over and above PET biomarkers of tau and neuroinflammation.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Did the study find a synergistic interaction between tau and neuroinflammation in predicting cognitive decline?

No, the interaction term was not significant, suggesting that the two pathological processes have an additive and independent effect on clinical progression.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Why might tau pathology in the anterior/medial temporal lobe be a weaker predictor of cognitive decline than tau in posterior temporo-parietal regions?

Tau deposition in the medial temporal lobe can occur as a normal feature of aging, whereas its spread to posterior neocortical regions drives clinical Alzheimer's progression.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What pathogenic role is proposed for neuroinflammation in the progression of tauopathy in Alzheimer's disease?

Activated microglia are hypothesized to drive and facilitate the spreading of tau pathology from the medial temporal lobe to neocortical regions.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What is a key biological limitation of using TSPO expression (targeted by 11C-PK11195) as a marker of microglial activation?

TSPO is not entirely specific to activated microglia; it is also expressed by other cell types, including astrocytes and vascular smooth muscle cells.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What is the main practical disadvantage of second-generation TSPO PET ligands compared to 11C-PK11195?

They require genetic screening for a single-nucleotide polymorphism (rs6971) because it significantly impacts their binding affinity and causes data heterogeneity.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What is the primary advantage of the 11C-PK11195 ligand over second-generation TSPO ligands in clinical studies?

Its binding affinity is less affected by the rs6971 genetic polymorphism, minimizing the need for genetic stratification.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Why can this study not make definitive inferences regarding the direction of causality between tau, microglial activation, and cognitive decline?

The neuroimaging assessments were cross-sectional at baseline, which prevents direct causal or mediation analysis over time.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What design limitation restricted the sample size to 26 for the multivariable predictive analyses?

Healthy controls only underwent one of the two PET scans to minimize radiation exposure, meaning only the patient group had complete multi-modal imaging.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

How did the study design minimize radiation exposure in healthy control subjects?

Healthy controls were divided into two separate groups: one group underwent 18F-AV-1451 (tau) PET, while the other group underwent 11C-PK11195 (TSPO) PET.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

How were regional PET data adjusted to correct for CSF contamination (partial volume effects) before kinetic modeling?

Regional PET values were divided by the mean regional grey plus white matter fraction derived from smoothed MRI tissue probability maps.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

How did the researchers handle data from left and right hemispheres to reduce the number of regions for analysis?

They combined left and right regional values to focus on 15 bilateral temporo-parietal regions, calculating volume-weighted averages of binding potential.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Why did the researchers estimate a linear slope rather than a non-linear (quadratic) slope for longitudinal cognitive decline?

Adding a non-linear (quadratic) term to the latent growth curve model did not improve the slope estimation.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

Which demographic variables differed significantly between the patient group and the healthy control group at baseline?

Education levels and baseline ACE-R scores showed significant differences, whereas age and sex did not.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

How many of the 14 baseline patients with MCI progressed clinically during the study or shortly thereafter?

Six converted or declined during the 3-year study, and three more converted subsequently.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

According to the authors, how can the findings of this study be applied to future clinical trials?

The findings support using PET imaging of tau pathology and microglial activation for predicting prognosis and stratifying patients in clinical trials.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified

What were the specific MMSE baseline score cut-offs required for eligibility in the study's patient and MCI groups?

All patients required an MMSE >12/30, and MCI patients specifically required an MMSE >24/30.

Source: Microglial activation and tau burden predict cognitive decline in Alzheimer's disease · DOI · quote verified